Abstract:BACKGROUND:Cholangiocarcinoma (CCA), consisting of intrahepatic (IHCCA), perihilar (PHCCA), and distal (DCCA) CCA, is a type of highly aggressive malignancy with a very dismal prognosis. Potential biomarkers and drug targets of CCA are urgently needed. As a new member of the Annexin (ANXA) family, the role of ANXA10 in the progression and prognosis of CCA is unknown.METHODS:Potential PHCCA biomarkers were screened by transcriptome sequencing of 5 pairs of PHCCA and adjacent tissues. The clinical significance of ANXA10 was evaluated by analyzing its correlation with clinicopathological variables, and the prognostic value of ANXA10 was evaluated with univariate and multivariate analyses. The function of ANXA10 in the epithelial-mesenchymal transition (EMT), proliferation, invasion and metastasis was detected with in vitro and in vivo experiments. Moreover, we screened the key molecule in ANXA10-induced CCA progression by mRNA sequencing and evaluated the correlation between PLA2G4A and ANXA10. The effect of PLA2G4A downstream signaling, including Cyclooxygenase 2, Prostaglandin E2(PGE2) and Signal transducer and activator of transcription 3(STAT3), on EMT and metastasis was further detected with in vitro and in vivo experiments.FINDINGS:ANXA10 expression was upregulated in PHCCA and DCCA but not in IHCCA. High ANXA10 expression was significantly associated with poor tumor differentiation and prognosis. ANXA10 promoted the proliferation, migration and invasion of the PHCCA cells. PLA2G4A expression was regulated by ANXA10 and high PLA2G4A predicted poor prognosis in PHCCA and DCCA. ANXA10 facilitated EMT and promoted metastasis by upregulating PLA2G4A expression, thus increasing PGE2 levels and activating STAT3.INTERPRETATION:ANXA10 was an independent prognostic biomarker of PHCCA and DCCA but not IHCCA. ANXA10 promoted the progression of PHCCA and facilitated metastasis by promoting the EMT process via the PLA2G4A/PGE2/STAT3 pathway. ANXA10, PLA2G4A and their downstream molecules, such as COX2 and PGE2, may be promising drug targets of PHCCA and DCCA.

Annexin A9 promotes cell proliferation by regulating the Wnt signaling pathway in colorectal cancer

Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis

ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway

Exosome‐derived ANXA9 functions as an oncogene in breast cancer

Expression of Annexin A5 is Associated with Higher Tumor Stage and Poor Prognosis in Colorectal Adenocarcinomas.

Inhibition of Annexin A3 Suppresses Cell Proliferation and Aggressiveness in Colorectal Cancer

Prognostic and Diagnostic Significance of Annexin A2 in Colorectal Cancer.

Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway

Annexin I and Tumor

Knockdown <i>annexin A8</i> Inhibits the Proliferation and Invasion of Cervical Cancer Cells

Differential Expression of ANXA1 in Benign Human Gastrointestinal Tissues and Cancers

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression

Identification And Characterization Of Ano9 In Stage Ii And Iii Colorectal Carcinoma

Annexin10 Promotes Extrahepatic Cholangiocarcinoma Metastasis by Facilitating EMT Via PLA2G4A/PGE2/STAT3 Pathway

Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.

SLC26A9 promotes colorectal tumorigenesis by modulating Wnt/β-catenin signaling

AnnexinA5 Might Suppress the Phenotype of Human Gastric Cancer Cells via ERK Pathway

ANXA1–GSK3β interaction and its involvement in NSCLC metastasis

ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6/JAK2/STAT3 pathway in papillary thyroid carcinoma

Annexin A4 and cancer